Table 1.

A summary of the main clinical and experimental studies for anti-hypertensive drugs and left ventricular hypertrophy (LVH).

Author and year	Main finding(s)
Costa et al., 199714	Enalaprilat inhibited isoproterenol-induced LVH action on cardiomyocytes, partially prevented the LVH and decreased the content of collagen fibers in rats.
Tan et al., 199222	Angiotensin-converting enzyme inhibition demonstrated promising myocardial remodeling effects in experimental models of hypertensive heart disease.
Bombig et al., 199623	Verapamil prevented the deleterious effects of isoproterenol in the myocardium of rats. This action was probably due to the prevention of myocardial hypertrophy and collagen tissue proliferation.
Sayegh F et al., 200524	Moexipril 15 mg once daily, administered for 24 weeks, resulted in a significant reversal of LVH in patients with essential hypertension.
Dahlöf et al., 200225	Losartan prevented more cardiovascular morbidity and deaths than did atenolol while inducing a similar reduction in blood pressure and is better tolerated in humans. Losartan seemed to confer benefits beyond a reduction in blood pressure.
Ferreira Filho et al., 200715	Enalaprilat increased the regression of hypertrophy in the left ventricle but not in the diaphragm or the gastrocnemius muscles.